Outcomes in women age 40 years and older with cytologically benign endometrial cells

Petra M. Casey, Mary M. Gallenberg, Thomas M. Kastner, Brigitte A. Barrette, Paula D.M. Chantigian, Lynne T. Shuster, Kathy L. MacLaughlin, Sumer K. Allensworth, Amy L. Weaver

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Objective: We sought to estimate cytologically benign endometrial cell (CBEC)-associated endometrial hyperplasia and cancer rates, and describe clinical and histologic outcomes. Study Design: Medical records of women age >40 years with CBEC in 2005 through 2010 were reviewed for clinical characteristics; assessment with endometrial biopsy, ultrasound, or hysteroscopy; and consequent outcomes. Results: Of 658 women, 281 (42.7%) were assessed: 39.4% of 330 premenopausal, and 46.0% of 328 postmenopausal women. Among these, cancer rate was 3.6% and differed between premenopausal (0.8%) and postmenopausal (6.0%) women (P =.019). Hyperplasia rate was similar in premenopausal (3.9%) and postmenopausal (3.3%) women. Of 20 assessed women with endometrial pathology, 4 (1 premenopausal) women with cancer and 4 (2 premenopausal) women with hyperplasia had no abnormal bleeding. Conclusion: Cancer was more common in postmenopausal women with assessed CBEC while hyperplasia was comparably distributed between premenopausal and postmenopausal women. Findings support CBEC assessment regardless of menopausal status or abnormal bleeding.

Original languageEnglish (US)
Pages (from-to)379.e1-379.e6
JournalAmerican journal of obstetrics and gynecology
Issue number5
StatePublished - Nov 2012


  • cytologically benign endometrial cells
  • endometrial cancer
  • endometrial hyperplasia

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Outcomes in women age 40 years and older with cytologically benign endometrial cells'. Together they form a unique fingerprint.

Cite this